The biggest predictors of survival following hematopoietic transplantation (HCT) for patients with hematologic malignancy are donor age and donor-recipient human leukocyte antigen (HLA)-match, according to an article published online ahead of print in Blood.1

Investigators evaluated the association between donor characteristics (ie, age, sex, parity, cytomegalovirus serostatus, HLA-match, and blood group ABO match) and survival following transplantation.

Continue Reading

Logistic or Cox regression models were used to examine the associations of donor characteristics with transplantation outcomes in 2 independent datasets: 1988 through 2006 (N=6,349; training cohort), and 2007 through 2011 (N=4,690; validation cohort).

Results after adjusting for patient disease and transplantation characteristics showed a survival benefit with grafts from young donors (18 to 32 years) who were HLA-matched to recipients (P < .001).

RELATED: Hematopoietic Cell Transplant Linked With Better Survival Outcomes

There was a 5.5% increase in the haqard ratio for overall mortality with every 10-year increment in age. Differences in HLA were associated with a decrease in survival.

Sex, parity, and cytomegalovirus serostatus were not linked to survival.

Investigators concluded that the effect of ABO matching on survival is modest and merits further study.


  1. Kollman C, Spellman SR, Zhang M-J, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy [published online ahead of print November 2, 2015]. Blood. doi: 10.1182/blood-2015-08-663823.